Distributor inventory | Tablet

Type 2 diabetes mellitus (as add-on to diet and exercise) to control post-meal and overall blood glucose, especially when single therapy is insufficient.

Voglibose is an alpha-glucosidase inhibitor that delays intestinal carbohydrate digestion and absorption, reducing post-meal blood sugar spikes. Metformin decreases hepatic glucose production and improves insulin sensitivity, helping lower fasting and postprandial glucose.

Oral tablet. Usually taken with meals as prescribed; voglibose-containing combinations are typically taken just before the first bite of a main meal. Swallow whole with water; do not skip meals. Dose and frequency depend on blood sugar control and kidney function.

Flatulence, abdominal pain, diarrhea, nausea, vomiting, loss of appetite, metallic taste, headache

Risk of hypoglycaemia increases if used with insulin or sulfonylureas; monitor glucose. Metformin may rarely cause lactic acidosis—risk increases with kidney impairment, dehydration, severe infection, heart/respiratory failure, liver disease, heavy alcohol use; stop and seek care if rapid breathing, severe weakness, abdominal pain occur. Avoid in severe renal impairment; periodic renal function monitoring required. Temporarily withhold metformin around iodinated contrast studies and major surgery as advised by a doctor. Voglibose may cause GI discomfort; titrate as directed.

Alcohol (increases lactic acidosis risk with metformin), iodinated contrast media, carbonic anhydrase inhibitors (e.g., topiramate/acetazolamide), cimetidine, diuretics, corticosteroids, thyroid hormones, beta-agonists, insulin and sulfonylureas (increased hypoglycaemia risk)

Store below 25°C in a cool, dry place. Protect from moisture and light. Keep out of reach of children.

Voglibose 0.2 mg + Metformin tablets (other brands), Vobit-M 0.2 Tablet, Voglib M 0.2 Tablet, Volibo M 0.2 Tablet, Vogmet 0.2 Tablet